Last reviewed · How we verify
SODAS methylphenidate HCl
SODAS methylphenidate HCl is a Sympathomimetic amine; CNS stimulant Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
SODAS methylphenidate HCl is a sustained-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system.
SODAS methylphenidate HCl is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that is classified as a dopamine transporter inhibitor. It is used to treat conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and Stimulant-Induced Euphoria, among others.
At a glance
| Generic name | SODAS methylphenidate HCl |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine, increasing their synaptic concentrations and enhancing neurotransmission in the brain. The SODAS (Spheroidal Oral Drug Absorption System) formulation provides extended-release delivery, allowing for once-daily dosing with a more gradual and sustained plasma concentration profile compared to immediate-release formulations.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist (PHASE4)
- A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults (PHASE4)
- Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODAS methylphenidate HCl CI brief — competitive landscape report
- SODAS methylphenidate HCl updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about SODAS methylphenidate HCl
What is SODAS methylphenidate HCl?
How does SODAS methylphenidate HCl work?
What is SODAS methylphenidate HCl used for?
Who makes SODAS methylphenidate HCl?
What drug class is SODAS methylphenidate HCl in?
What development phase is SODAS methylphenidate HCl in?
What are the side effects of SODAS methylphenidate HCl?
What does SODAS methylphenidate HCl target?
Related
- Drug class: All Sympathomimetic amine; CNS stimulant drugs
- Target: All drugs targeting Dopamine transporter (DAT); Norepinephrine transporter (NET)
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Neurology; Psychiatry
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD)
- Indication: Drugs for Narcolepsy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing